Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Wustrow

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Medicinal Chemistry|July 16, 2020
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint InhibitorsOmar Robles, Jeffrey J Jackson, Lisa Marshall, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2005
Carboxylate bioisosteres of gabapentinCarmen E Burgos-Lepley, Lisa R Thompson, Clare O Kneen, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2006
Carboxylate bioisosteres of pregabalinJacob B Schwarz, Norman L Colbry, Zhijian Zhu, et al.
Journal of Medicinal Chemistry|July 14, 2026
Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor ImmunityOmar Robles, Dirk G Brockstedt, Joel Aponte-Guzman, et al.
Journal of Medicinal Chemistry|July 2, 2019
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T<sub>reg</sub> Trafficking into the Tumor MicroenvironmentJeffrey J Jackson, John M Ketcham, Ashkaan Younai, et al.
Journal of Medicinal Chemistry|April 18, 2020
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor ActivityPaul R Leger, Dennis X Hu, Berenger Biannic, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseasesLain-Yen Hu, Peter A Boxer, Suzanne R Kesten, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Medicinal Chemistry|July 16, 2020
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint InhibitorsOmar Robles, Jeffrey J Jackson, Lisa Marshall, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2005
Carboxylate bioisosteres of gabapentinCarmen E Burgos-Lepley, Lisa R Thompson, Clare O Kneen, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2006
Carboxylate bioisosteres of pregabalinJacob B Schwarz, Norman L Colbry, Zhijian Zhu, et al.
Journal of Medicinal Chemistry|July 14, 2026
Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor ImmunityOmar Robles, Dirk G Brockstedt, Joel Aponte-Guzman, et al.
Journal of Medicinal Chemistry|July 2, 2019
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T<sub>reg</sub> Trafficking into the Tumor MicroenvironmentJeffrey J Jackson, John M Ketcham, Ashkaan Younai, et al.
Journal of Medicinal Chemistry|April 18, 2020
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor ActivityPaul R Leger, Dennis X Hu, Berenger Biannic, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseasesLain-Yen Hu, Peter A Boxer, Suzanne R Kesten, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Pageof 2